Effects of intratympanic injection of latanoprost in Meniere's disease: a randomized, placebo-controlled, double-blind, pilot study.
OBJECTIVE
To determine the short-term effects of latanoprost, a selective FP prostanoid receptor agonist, in Meniere's disease.


METHODS
Latanoprost was administered by intratympanic injection once daily for 3 days. Before the first injection (day 1) and on days 5 and 15, hearing and tinnitus were determined. The patients assessed vertigo on a visual analogue scale on days 1-15. The study was randomized, double-blind, and placebo-controlled.


RESULTS
Latanoprost reduced vertigo/dysequilibrium around 30% (P < 0.05), and improved speech discrimination around 15% (P < 0.05). Tinnitus loudness deteriorated after injection of placebo (P < 0.01) but not after latanoprost. Side effects were few.


CONCLUSIONS
Latanoprost alleviated vertigo/dysequilibrium and improved hearing. The results indicate that the drug potentially could be useful for treatment of Meniere's disease.
Rask-Andersen
Helge
H
Department of Otosurgery, University Hospital, Uppsala, Sweden. helge.rask-andersen@akademiska.se
Friberg
Ulla
U
Johansson
Marianne
M
Stjernschantz
Johan
J
D000328:Adult; D004311:Double-Blind Method; D005260:Female; D006309:Hearing; D006801:Humans; D015552:Injections, Intralesional; D000077338:Latanoprost; D008297:Male; D008575:Meniere Disease / Q000188:drug therapy*; D008875:Middle Aged; D010865:Pilot Projects; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage* / Q000627:therapeutic use; D013067:Speech Perception; D016896:Treatment Outcome; D014432:Tympanic Membrane; D014717:Vertigo
D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost